Back

HFpEF and glycemic variability: GHIDD Trial

2 September 2024 (14:00 - 14:40)
Organised by: Logo
Congress Presentation Part of: Metabolic syndrome and heart disease (2) Diabetes and the Heart ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Giovanni Fazio

Polimedic, Palermo (Italy)

4 More presentations in this session

Presentation thumbnail
Telomere length across spectrum of metabolic health.
Associate Professor T. Osadnik (Zabrze, PL)
Abstract Slides Video
Presentation thumbnail
Spermidine attenuates left ventricular dysfunction in estrogen deprived aging rats through mitigating lipid peroxidation and mitochondrial dysfunction
Doctor C. Maneechote (Chiang Mai, TH)
Abstract Slides Video
Presentation thumbnail
Empagliflozin's role in reducing ventricular repolarization heterogeneity: insights into cardiovascular mortality decline from the EMPATHY-HEART trial
Doctor C. Lauretti (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Elevated levels of plasma inactive stromal cell derived factor-1a predict long-term adverse outcomes in diabetic patients with coronary artery disease
Assistant Professor Y. Chikata (Tokyo, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Metabolic syndrome and heart disease (2)

The Event

Event poster

ESC Congress 2024

2 September 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Visit-to-visit glycemic variability is associated with the incidence of heart failure with improved ejection fraction
thumbnail
Congress Presentation
Association of long-term visit-to-visit glycemic variability with risk of adverse clinical outcomes in diabetic patients with heart failure with preserved ejection fraction
thumbnail
Congress Session
The therapeutic conundrum in HFpEF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources